ES2076263T3 - Formulacion farmaceutica inyectable estable, para acido folico y sales de leucovorina y procedimiento. - Google Patents

Formulacion farmaceutica inyectable estable, para acido folico y sales de leucovorina y procedimiento.

Info

Publication number
ES2076263T3
ES2076263T3 ES90112426T ES90112426T ES2076263T3 ES 2076263 T3 ES2076263 T3 ES 2076263T3 ES 90112426 T ES90112426 T ES 90112426T ES 90112426 T ES90112426 T ES 90112426T ES 2076263 T3 ES2076263 T3 ES 2076263T3
Authority
ES
Spain
Prior art keywords
salts
folic acid
leukovorine
procedure
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90112426T
Other languages
English (en)
Inventor
Bruce Edwin Haeger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2076263T3 publication Critical patent/ES2076263T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICIONES ACUOSAS INYECTABLES QUE CONTIENEN ACIDO FOLICO Y LEUCOVORINA Y SUS SALES, INCLUYENDO OPCIONALMENTE BENCILO ALCOHOL, CLORURO DE SODIO Y AGENTES PARA AJUSTAR PH SE ESTABILIZAN Y CUAJAN EN EL MARGEN DE 6 A 10 AÑADIENDO UNA COMBINACION DE TROMETAMINA Y MONOTIOGLICEROL. TALES COMPOSICIONES PERMANECEN ESTABLES POR PERIODOS PROLONGADOS, INCLUSO CUANDO SE EXPONEN A LA LUZ SOLAR.
ES90112426T 1989-08-21 1990-06-29 Formulacion farmaceutica inyectable estable, para acido folico y sales de leucovorina y procedimiento. Expired - Lifetime ES2076263T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39657389A 1989-08-21 1989-08-21

Publications (1)

Publication Number Publication Date
ES2076263T3 true ES2076263T3 (es) 1995-11-01

Family

ID=23567787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90112426T Expired - Lifetime ES2076263T3 (es) 1989-08-21 1990-06-29 Formulacion farmaceutica inyectable estable, para acido folico y sales de leucovorina y procedimiento.

Country Status (11)

Country Link
EP (1) EP0416232B1 (es)
JP (1) JP3043381B2 (es)
KR (1) KR0159768B1 (es)
AT (1) ATE126438T1 (es)
AU (1) AU628211B2 (es)
CA (1) CA2023563C (es)
DE (1) DE69021673T2 (es)
DK (1) DK0416232T3 (es)
ES (1) ES2076263T3 (es)
GR (1) GR3017143T3 (es)
PT (1) PT95026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
CH687062A5 (de) * 1994-02-14 1996-09-13 Cerbios Pharma Sa Konzentrierte Injektionsloesung von Alkalimetallsalzen von reduzierten Folaten.
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
CN1748704B (zh) * 2004-09-15 2011-05-04 尼普洛株式会社 注射用水溶液制剂及其稳定化方法
JP4545632B2 (ja) * 2005-04-25 2010-09-15 株式会社 伊藤園 葉酸含有組成物及び葉酸の安定化方法
JP4919024B2 (ja) * 2006-11-16 2012-04-18 横河電機株式会社 圧力センサ
JP4906546B2 (ja) * 2007-03-15 2012-03-28 株式会社ヤクルト本社 レボホリナート含有水溶液製剤
JP6057254B2 (ja) * 2013-01-23 2017-01-11 パナソニックIpマネジメント株式会社 赤外線受光ユニット、赤外線式ガスセンサ
CN104937385B (zh) 2013-01-21 2017-11-03 松下知识产权经营株式会社 红外线检测元件、红外线检测器及红外线式气体传感器
EP2799060A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition comprising levoleucovorin
EP2799061A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
CA2974953A1 (en) * 2015-01-27 2016-08-04 La Vita Compounding Pharmacy Stable 5-methyltetrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
EP3917495A1 (en) * 2019-01-31 2021-12-08 scPharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
CN118059042A (zh) * 2024-04-17 2024-05-24 成都瑞尔医药科技有限公司 一种亚叶酸钙注射液及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695860A (en) * 1952-04-29 1954-11-30 American Cyanamid Co Stabilized pteroyl solutions
US4071620A (en) * 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
WO1988004927A1 (en) * 1986-12-31 1988-07-14 Davirand, Inc. Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid

Also Published As

Publication number Publication date
EP0416232B1 (en) 1995-08-16
PT95026A (pt) 1991-04-18
ATE126438T1 (de) 1995-09-15
AU628211B2 (en) 1992-09-10
PT95026B (pt) 1997-12-31
CA2023563A1 (en) 1991-02-22
DK0416232T3 (da) 1995-09-18
AU6116590A (en) 1991-02-21
EP0416232A3 (en) 1992-01-02
JPH0390026A (ja) 1991-04-16
GR3017143T3 (en) 1995-11-30
CA2023563C (en) 2000-02-22
JP3043381B2 (ja) 2000-05-22
DE69021673D1 (de) 1995-09-21
KR0159768B1 (ko) 1998-12-01
DE69021673T2 (de) 1996-05-02
KR910004194A (ko) 1991-03-28
EP0416232A2 (en) 1991-03-13

Similar Documents

Publication Publication Date Title
ES2076263T3 (es) Formulacion farmaceutica inyectable estable, para acido folico y sales de leucovorina y procedimiento.
DE122011000014I1 (de) Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES541521A0 (es) Un procedimiento para la preparacion de piridazinaminas.
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
IT1243435B (it) Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
ES2073222T3 (es) Sales estables de acido 5,10-metilen-tetrahidrofolico.
ATE97572T1 (de) Azelastin enthaltende arzneimittel mit kontrollierter wirkstoffabgabe.
DE3863859D1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
ATE306475T1 (de) Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung
NO902488L (no) Karboplatinapreparat.
AR245591A1 (es) Una composicion oral estable, con propiedades antiplaca y antigingivales mejoradas.
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
FI910112A (fi) Preparat foer lokalt bruk.
ATE117313T1 (de) Stabile lösungen von rebeccamycinderivaten sowie deren herstellung.
PT94040A (pt) Processo para preparacao de sais cristalinos, estaveis, muito soluveis em agua de mono-hidrato de 2',3'-didesoxi-2',3'-didesidro-timidina, de mono-hidrato de 2',3'-didesoxi-2'-fluoro -inosina com actividade antiviral e de composicoes farmaceuticas que os contem
ES8203221A1 (es) Procedimiento para preparar una composicion antihelmintica acuosa termicamente reversible
BR9201625A (pt) Composicao herbicida,metodo de preparacao de uma composicao,uso e metodos para reduzir a fitotoxicidade e para a destruicao e controle pos-emergentes seletivos de ervas daninhas
NO301805B1 (no) Fremgangsmåte for fremstilling av et stabilt, galenisk, vandig preparat av erytropoietin
DE69113675D1 (de) Verwendung von Naproxen als Mydriatikum.
TH2950B (th) สารแขวนลอยซูครัลเฟท

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 416232

Country of ref document: ES